{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:35:10Z","timestamp":1787063710246,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>In April 2023, the National Comprehensive Cancer Network endorsed neoadjuvant immunotherapy for select patients with nonmetastatic mismatch repair deficient colon cancer. Approximately 15% of incident colon cancers are mismatch repair deficient, resulting in a distinct molecular subtype with high microsatellite instability that is responsive to immune checkpoint inhibition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To describe the existing evidence supporting neoadjuvant immunotherapy for mismatch repair deficient, microsatellite unstable nonmetastatic colon cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>A medical librarian performed PubMed, Embase, and Web of Science searches most recently on April 24, 2023. The PubMed search was re-run on September 26, 2023, to identify any additional studies published between April 24 and September 26, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION:<\/jats:title>\n                    <jats:p>Two authors screened titles and abstracts in the published studies. The inclusion criteria were 1) English language, 2) adults with primary cancer of the colon, 3) nonmetastatic disease, 4) neoadjuvant immunotherapy, and 5) reporting on 10 or more cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>INTERVENTION:<\/jats:title>\n                    <jats:p>Neoadjuvant immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN OUTCOME MEASUREs:<\/jats:title>\n                    <jats:p>Safety (grade 3+ treatment-related adverse events) and efficacy (complete pathologic responses).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>From 7691 studies identified, 6370 were screened and 8 were included. Various agents, dosing regimens, and treatment durations were used, with durations of immunotherapy ranging from 1 to 16 cycles. Complete R0 resections were consistently achieved in 98% to 100% of resections. Of patients who received neoadjuvant immunotherapy and underwent resection, 50% to 91% had ypT0N0 pathology. The safety profiles were generally favorable, with grade 1 to 2 treatment-related adverse events (mostly immune-related) during immunotherapy reported in 22.2% to 70% of patients. Postoperative complications after neoadjuvant immunotherapy were reassuring, with no severe complications reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS:<\/jats:title>\n                    <jats:p>Small number of heterogeneous and uncontrolled studies precluding a meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Neoadjuvant immune checkpoint inhibition is associated with high rates of pathologic complete responses in locally advanced colon cancer. The literature is limited, particularly for postoperative outcomes, and more studies are needed to understand the safety and positioning of these regimens in the neoadjuvant context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dcr.0000000000003263","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T19:00:14Z","timestamp":1710356414000},"page":"762-771","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Systematic Review of Neoadjuvant Immunotherapy for Mismatch Repair Deficient Locally Advanced Colon Cancer: An Emerging Strategy"],"prefix":"10.1097","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0877-6500","authenticated-orcid":false,"given":"Anthony","family":"Loria","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Ammann","sequence":"additional","affiliation":[{"name":"Section of Colon and Rectal Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olugbenga O.","family":"Olowokure","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Paquette","sequence":"additional","affiliation":[{"name":"Section of Colon and Rectal Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla F.","family":"Justiniano","sequence":"additional","affiliation":[{"name":"Section of Colon and Rectal Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"R1-20250505","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R2-20250505","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMc2210175","article-title":"Prevalence of mismatch-repair deficiency in rectal adenocarcinomas.","volume":"387","author":"Papke","year":"2022","journal-title":"N Engl J Med"},{"key":"R3-20250505","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1200\/JCO.2008.17.5950","article-title":"Feasibility of screening for Lynch syndrome among patients with colorectal cancer.","volume":"26","author":"Hampel","year":"2008","journal-title":"J Clin Oncol"},{"key":"R4-20250505","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jmoldx.2016.07.010","article-title":"Detection of mismatch repair deficiency and microsatellite instability in colorectal adenocarcinoma by targeted next-generation sequencing.","volume":"19","author":"Nowak","year":"2017","journal-title":"J Mol Diagn"},{"key":"R5-20250505","first-page":"148","article-title":"Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.","volume":"145","author":"Kim","year":"1994","journal-title":"Am J Pathol"},{"key":"R6-20250505","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3390\/cancers13020300","article-title":"Prognostic and predictive values of mismatch repair deficiency in non-metastatic colorectal cancer.","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R7-20250505","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors.","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R9-20250505","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R10-20250505","doi-asserted-by":"crossref","first-page":"1044353","DOI":"10.3389\/fimmu.2023.1044353","article-title":"Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"R11-20250505","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2022.7060","article-title":"Neoadjuvant immunotherapy leads to major response and low recurrence in localized mismatch repair-deficient colorectal cancer.","volume":"21","author":"Xiao","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R12-20250505","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.clcc.2022.11.004","article-title":"Single-agent neoadjuvant immunotherapy with a PD-1 antibody in locally advanced mismatch repair-deficient or microsatellite instability-high colorectal cancer.","volume":"22","author":"Pei","year":"2023","journal-title":"Clin Colorectal Cancer"},{"key":"R13-20250505","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors.","volume":"41","author":"Ludford","year":"2023","journal-title":"J Clin Oncol"},{"key":"R14-20250505","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4240\/wjgs.v15.i2.222","article-title":"Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies.","volume":"15","author":"Li","year":"2023","journal-title":"World J Gastrointest Surg"},{"key":"R15-20250505","doi-asserted-by":"crossref","first-page":"913483","DOI":"10.3389\/fimmu.2022.913483","article-title":"Efficacy and Safety of Neoadjuvant monoimmunotherapy with PD-1 Inhibitor for dMMR\/MSI-H locally advanced colorectal cancer: a single-center real-world study.","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"R16-20250505","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R17-20250505","doi-asserted-by":"crossref","first-page":"e996","DOI":"10.1097\/DCR.0000000000002466","article-title":"Neoadjuvant immune checkpoint inhibition improves organ preservation in T4bM0 colorectal cancer with mismatch repair deficiency: a retrospective observational study.","volume":"66","author":"Han","year":"2023","journal-title":"Dis Colon Rectum"},{"key":"R18-20250505","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"R19-20250505","first-page":"746","article-title":"Identification of risk factors for lymph node metastasis of colorectal cancer.","volume":"54","author":"Takano","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"R20-20250505","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archsurg.140.9.881","article-title":"Assessing the quality of colorectal cancer staging: documenting the process in improving the staging of node-negative colorectal cancer.","volume":"140","author":"Wong","year":"2005","journal-title":"Arch Surg"},{"key":"R21-20250505","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1477-7819-10-39","article-title":"Results after multivisceral resections of locally advanced colorectal cancers: an analysis on clinical and pathological t4 tumors.","volume":"10","author":"Gezen","year":"2012","journal-title":"World J Surg Oncol"},{"key":"R22-20250505","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"key":"R23-20250505","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 Blockade in mismatch repair-deficient, locally advanced rectal cancer.","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"R25-20250505","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"R26-20250505","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1200\/JCO.2022.40.16_suppl.3510","article-title":"Nivolumab (NIVO) \u00b1 ipilimumab (IPI) in patients (pts) with microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): five-year follow-up from CheckMate 142.","volume":"40","author":"Overman","year":"2022","journal-title":"J Clin Oncol"},{"key":"R27-20250505","doi-asserted-by":"crossref","first-page":"S1389","DOI":"10.1016\/j.annonc.2022.08.016","article-title":"LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study.","volume":"33","author":"Chalabi","year":"2022","journal-title":"Ann Oncol"},{"key":"R28-20250505","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/bjs\/znac050","article-title":"Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient\/microsatellite instability-high locally advanced, non-metastatic colorectal cancer.","volume":"109","author":"Kothari","year":"2022","journal-title":"Br J Surg"}],"container-title":["Diseases of the Colon &amp; Rectum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DCR.0000000000003263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T20:02:23Z","timestamp":1746475343000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DCR.0000000000003263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/dcr.0000000000003263","relation":{},"ISSN":["0012-3706"],"issn-type":[{"value":"0012-3706","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,13]]}}}